Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX · NASDAQ Global Market
+$0.00 today
Vol 1.50M · Avg 0.54M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:BCAX · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$157.3M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-2.78, tying the income statement back to per-share earnings.
Income Statement
Annual data · 4 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $1.0B | $809.6M | $921.6M |
| Cost of Revenue | $0 | $0 | $0 | $0 | $344.8M | $725.6M | $804.0M |
| Gross Profit | $0 | $0 | $0 | $0 | $10.3B | $8.9B | $7.6B |
| Gross Margin | — | — | — | — | 45.5% | 9.8% | 28.9% |
| Research & Development | $125.1M +96.6% | $63.6M +107.8% | $30.6M -2.2% | $31.3M | $378.4M | $983.2M | $1.3B |
| Selling, General & Admin | $30.5M +62.5% | $18.8M +102.4% | $9.3M +46.2% | $6.3M | $1.4B | $620.6M | $923.0M |
| Operating Expenses | $155.6M +88.9% | $82.4M +106.5% | $39.9M +5.9% | $37.7M | $3.6B | $5.3B | $7.0B |
| Depreciation & Amortization | $105.0K +87.5% | $56.0K +194.7% | $19.0K +90.0% | $10.0K | $1.2B | $374.2M | $1.2B |
| EBITDA | -$137.6M -103.1% | -$67.8M -30.4% | -$52.0M -37.7% | -$37.7M | $12.6B | -$15.2B | $6.8B |
| EBITDA Margin | — | — | — | — | 10.0% | 5.6% | 46.3% |
| Operating Income | -$155.6M -88.9% | -$82.4M -106.5% | -$39.9M -5.9% | -$37.7M | $10.6B | $12.3B | $14.0B |
| Operating Margin | — | — | — | — | 18.7% | 16.6% | 24.1% |
| Interest Income | $17.9M +22.6% | $14.6M +1009.7% | $1.3M +32750.0% | $4.0K | $1.3B | -$1.5B | -$1.6B |
| Interest Expense | $0 | $0 | $0 -100.0% | $112.0K | $969.2M | $1.1B | $1.0B |
| Other Income / Expenses | $17.9M +22.6% | $14.6M +220.6% | -$12.1M -6331.4% | -$188.0K | -$1.6B | -$1.5B | $1.4B |
| Income Before Tax | -$137.7M -103.1% | -$67.8M -30.5% | -$52.0M -37.4% | -$37.8M | -$15.6B | $3.3B | $4.9B |
| Pre-Tax Margin | — | — | — | — | 13.3% | 20.8% | 18.7% |
| Income Tax Expense | $217.0K +16.0% | $187.0K +3640.0% | $5.0K +400.0% | $1.0K | $666.8M | $1.3B | -$1.6B |
| Net Income | -$137.9M -102.9% | -$68.0M -30.8% | -$52.0M -37.4% | -$37.8M | $5.0B | $4.9B | $4.8B |
| Net Margin | — | — | — | — | 7.4% | 12.4% | 17.5% |
| EPS (Basic) | -$3 -101.6% | -$1 -25.0% | -$1 -37.0% | -$1 | $1.2B | $400.8M | $703.2M |
| EPS (Diluted) | -$3 -101.6% | -$1 -25.0% | -$1 -37.0% | -$1 | $620.6M | $766.2M | $609.4M |
| Weighted Avg Shares | $54.7M +0.5% | $54.4M +5.1% | $51.8M +0.0% | $51.8M | $892.2M | $757.8M | $925.8M |
| Weighted Avg Shares (Diluted) | $54.7M +0.5% | $54.4M +5.1% | $51.8M +0.0% | $51.8M | $319.6M | $1.2B | $924.4M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Tango Therapeutics, Inc.
NASDAQ:TNGX
$3.56B
Septerna, Inc.
NASDAQ:SEPN
$1.56B
Fortrea Holdings Inc.
NASDAQ:FTRE
$1.44B
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.12B
Savara Inc.
NASDAQ:SVRA
$1.11B
Kura Oncology, Inc.
NASDAQ:KURA
$852.23M
Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
$848.92M
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
$734.91M
Prime Medicine, Inc.
NASDAQ:PRME
$562.62M
ProKidney Corp.
NASDAQ:PROK
$261.51M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does BCAX generate?
Bicara Therapeutics Inc. Common Stock (BCAX) reported $0.00 of revenue in fiscal 2025.
Is BCAX profitable?
Bicara Therapeutics Inc. Common Stock (BCAX) reported -$137,950,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.